- ReWalk to submit first instances for Medicare protection by way of Medicare Administrative Contractors (MACs)
- Facilities for Medicare and Medicaid Companies (CMS) affirms that the MACs have discretion to cowl and reimburse the ReWalk exoskeleton
- CMS additionally plans to additional deliberate on a profit class designation for the ReWalk exoskeleton and has mentioned that it’s going to present extra info within the close to future
MARLBOROUGH, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) — ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk”, or the “Firm”), a number one producer of robotic medical know-how for folks with decrease extremity disabilities, is asserting that the Firm will start submitting Medicare instances following CMS’s September 26, 2022, announcement affirming that the MACs have discretion to cowl and reimburse for the ReWalk exoskeleton. ReWalk Robotics is actively engaged with CMS in its dedication to guage advanced superior applied sciences like exoskeletons.
“We’re happy CMS has supplied a pathway to submit instances whereas they proceed to deliberate on the profit class designation,” mentioned Larry Jasinski, Chief Govt Officer (CEO) of ReWalk. “In gentle of this announcement, ReWalk will start submitting instances for Medicare beneficiaries with spinal cord injury (SCI) to the MACs. All sufferers with spinal cord injury deserve entry to revolutionary applied sciences that considerably enhance their well being. We are going to proceed to advocate for Medicare to supply these progressive life-changing gadgets to beneficiaries with SCI.”
That is the most recent step in ReWalk’s efforts to broaden entry to the Firm’s exoskeletons for Medicare beneficiaries with SCI. Research have proven that the power to ambulate with an exoskeleton has a profound and helpful influence on well being outcomes for people with SCI, together with by way of improved psychological well being, elevated gastrointestinal (GI) operate and different enhancements on the well being penalties of a SCI. ReWalk has prioritized working with payers like Medicare to make sure protection of and entry to exoskeleton applied sciences for people who’re paralyzed or disabled attributable to SCI, so they can as soon as once more expertise the well being and well-being advantages of purposeful ambulation.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for people with decrease limb disabilities on account of SCI or stroke. ReWalk’s mission is to basically change the standard of life for people with decrease limb incapacity by way of the creation and improvement of market main robotic applied sciences. Based in 2001, ReWalk has headquarters within the U.S., Israel and Germany. For extra info on the ReWalk programs, please go to rewalk.com
ReWalk® and ReStore® are registered logos of ReWalk Robotics Ltd. in america and different jurisdictions.
Along with historic info, this press launch comprises forward-looking statements inside the that means of the U.S. Personal Securities Litigation Reform Act of 1995, Part 27A of the U.S. Securities Act of 1933, as amended, and Part 21E of the U.S. Securities Trade Act of 1934, as amended. Such forward-looking statements could embrace projections concerning ReWalk’s future efficiency and different statements that aren’t statements of historic truth and, in some instances, could also be recognized by phrases like “anticipate,” “assume,” “imagine,” “proceed,” “might,” “estimate,” “anticipate,” “intend,” “could,” “plan,” “potential,” “predict,” “venture,” “future,” “will,” “ought to,” “would,” “search” and comparable phrases or phrases. The forward-looking statements contained on this press launch are primarily based on administration’s present expectations, that are topic to uncertainty, dangers and adjustments in circumstances which are troublesome to foretell and lots of of that are outdoors of ReWalk’s management. Essential elements that might trigger ReWalk’s precise outcomes to vary materially from these indicated within the forward-looking statements are extra totally mentioned in ReWalk’s periodic filings with the Securities and Trade Fee (“SEC”), together with the danger elements described beneath the heading “Threat Elements” in ReWalk’s annual report on Kind 10-Okay and 10-Okay/A for the yr ended December 31, 2021 filed with the SEC and different paperwork subsequently filed with or furnished to the SEC. Any forward-looking assertion made on this press launch speaks solely as of the date hereof. Elements or occasions that might trigger ReWalk’s precise outcomes to vary from the statements contained herein could emerge once in a while, and it’s not attainable for ReWalk to foretell all of them. Besides as required by regulation, ReWalk undertakes no obligation to publicly replace any forward-looking statements, whether or not on account of new info, future developments or in any other case.
Chief Monetary Officer
ReWalk Robotics Ltd.
T: +1 508-281-7274